YOJ has performed exceptionally well , far more than what the sp suggest.
The rise in sp from 8/17 to 1/18 coinciding with date of release of 3B suggest a rise of 308% (3x bagger) but if you work on the basis of mcap, it was a rise of 476% (4.76x bagger) (yup the valuation increased almost 5 fold in 5 months!). The share base ballooned due in part to the performance shares.
Column 1 Column 2 Column 3 Column 4 0 Period Share Base (mil) Price on date of release of 3B Mcap ($m) 1 Jan-18 748.44 $ 0.2650 198.34 2 Aug-17 484.44 $ 0.0860 41.66 3 Jun-17 440.00 $ 0.0600 26.40 4 May-17 423.70 $ 0.0770 32.62
So even if the stock has large potential ahead of it, it is certainly due for consolidation.
Whether the sp can hold its valuation in the absence of concrete evidence in materialisation of revenues (from announced deals) will largely be dictated by continued belief in the stock and support from newsletter.
- Forums
- ASX - By Stock
- YOJ
- Ann: Quarterly Activity Statement and App 4C Dec Q 17
YOJ
yojee limited
Add to My Watchlist
5.56%
!
38.0¢

Ann: Quarterly Activity Statement and App 4C Dec Q 17, page-55
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
38.0¢ |
Change
0.020(5.56%) |
Mkt cap ! $122.8M |
Open | High | Low | Value | Volume |
37.5¢ | 40.0¢ | 37.0¢ | $408.7K | 1.071M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 58162 | 38.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
38.5¢ | 4000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 58162 | 0.380 |
1 | 11000 | 0.375 |
1 | 27027 | 0.370 |
6 | 16238 | 0.360 |
5 | 59329 | 0.350 |
Price($) | Vol. | No. |
---|---|---|
0.385 | 4000 | 1 |
0.390 | 10000 | 1 |
0.400 | 2054 | 1 |
0.410 | 33808 | 1 |
0.450 | 8000 | 2 |
Last trade - 15.59pm 26/06/2025 (20 minute delay) ? |
Featured News
YOJ (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online